India’s Cadila Prescription drugs, one of many largest privately held pharma corporations within the nation, shut down its formulations manufacturing plant in Ahmedabad on Thursday after greater than two dozen of its staff examined constructive for the brand new coronavirus.
A senior authorities official mentioned late on Thursday that 5 staff had examined constructive for COVID-19 six days again, whereas 21 others examined constructive this week.
“We had collected samples of 30 staff of Cadila on Might 5, and 21 of the samples returned constructive a day later,” mentioned Arun Mahesh Babu, the District Improvement Officer of Ahmedabad.
He added the plant was ordered to be shut down on Thursday, 95 staff had been quarantined and sanitization work on the web site had begun.
The incident comes simply days after India started to ease a few of its lockdown restrictions aimed toward stopping the unfold of the brand new coronavirus. Ahmedabad, nevertheless, is among the extra badly affected cities in India and has moved to tighten restrictions this week.
In an announcement, Cadila Prescription drugs mentioned, “Just lately, 26 of our staff from our Dholka manufacturing facility examined constructive for COVID-19. Following this, now we have closed our operations on our personal.”
The corporate additionally mentioned it’s cooperating with the native administration to make sure the security and safety of its facility and environment.
In addition to Dholka, Cadila Prescription drugs has manufacturing services in different elements of India and in Ethiopia. The corporate is a significant producer of lively pharmaceutical elements (API) – the important thing elements utilized in making a drug.
(Aside from the headline, this story has not been edited by NDTV employees and is revealed from a syndicated feed.)